Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD

The two main subsets of nonalcoholic fatty liver disease (NAFLD) include: (1) nonalcoholic fatty liver (NAFL), the more common and non-progressive subtype; and (2) nonalcoholic steatohepatitis (NASH), the less common subtype, which has the potential to progress to advanced liver damage. Current trea...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Pratima Dibba, Andrew A. Li, Brandon J. Perumpail, Nimy John, Sandy Sallam, Neha D. Shah, Waiyee Kwong, George Cholankeril, Donghee Kim, Aijaz Ahmed
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2018-09-01
Series:Diseases
Assuntos:
NAFLD
NASH
nonalcoholic fatty liver disease
drug therapy
chemokine receptor 2 and 5
galectin-3 protein
toll-like receptor 4
fibroblast growth factor 19
selective thyroid hormone receptor-beta
apoptosis signal-regulating kinase 1
acetyl-coenzyme A carboxylase
farnesoid X receptor
inflammasomes
Acceso en liña:http://www.mdpi.com/2079-9721/6/3/83
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares